Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
X. Huang, X. Liu, Y. Luo, Y. Zhou, Y. Guo, C. Xie (Guangzhou, Meizhou, China). Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients. Eur Respir J 2013; 42: Suppl. 57, 697

Member's Comments

No comment yet.

Related content which might interest you: Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Evaluation of IL-8 and MEF25-75 in patients with severe COPD who were treated with combined therapy of ICSs / LABAs plus tiotropium bromide Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014 The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD Source: Eur Respir J 2007; 30: Suppl. 51, 356s Year: 2007 Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015